Search research articles
Contact Us
Filters
Showing results (41-50 of 71) with videos related to
Page
of 8
Sort By:
Cancer
|
June 16, 2018
Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials
Divine E Ediebah, Chantal Quinten, Corneel Coens, et al.
Head & Neck
|
March 25, 2009
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib
Laura Vidal, Ming S Tsao, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.
Genomics
|
April 23, 2013
Clinical genomics information management software linking cancer genome sequence and clinical decisions
Stuart Watt, Wei Jiao, Andrew M K Brown, et al.
Investigational New Drugs
|
July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Susan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Cancer
|
January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
Saskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2009
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
Tanios Bekaii-Saab, Joseph Markowitz, Nichole Prescott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
Evanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 71) with videos related to
Sort By:
Page
of 8
Cancer
|
June 16, 2018
Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials
Divine E Ediebah, Chantal Quinten, Corneel Coens, et al.
Head & Neck
|
March 25, 2009
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib
Laura Vidal, Ming S Tsao, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.
Genomics
|
April 23, 2013
Clinical genomics information management software linking cancer genome sequence and clinical decisions
Stuart Watt, Wei Jiao, Andrew M K Brown, et al.
Investigational New Drugs
|
July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Susan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Cancer
|
January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
Saskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2009
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas
Tanios Bekaii-Saab, Joseph Markowitz, Nichole Prescott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2005
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
Evanthia Galanis, Jan C Buckner, Matthew J Maurer, et al.
Page
of 8